Goldman Sachs Upgrades Vertex Pharmaceuticals To Buy

Analysts at Goldman Sachs upgraded Vertex Pharmaceuticals VRTX from Neutral to Buy. The target price for Vertex Pharmaceuticals has been raised from $109 to $131. Vertex Pharma shares have gained 16.00% over the past 52 weeks, while the S&P 500 index has surged 20.10% in the same period. Vertex Pharmaceuticals' shares rose 0.22% to $95.25 in pre-market trading.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: UpgradesAnalyst RatingsGoldman Sachs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!